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Besides cholesterol lowering, statins exert several non-lipid (so-called
“pleiotropic”) actions [1-4]; statins improve vascular endothelial function
and exert antithrombotic and anti-inflammatory effects [1, 2]. Statins are
also associated with a reduced incidence of coronary risk and cardiovas-
cular events [5-7].
A recent study demonstrated that statin withdrawal increased the risk
of subarachnoid haemorrhage by > 60% compared with non-use (odds
ratio (OR) 1.62; 95% confidence interval (CI) 0.96-2.73) and by > 2-fold com-
pared with current use (OR 2.34; 95% CI 1.35-4.05) [8]. An earlier study
showed that, compared with continuous statin use, statin withdrawal is
associated with an almost 3-fold increase in first-year mortality rates after
an ischaemic stroke episode (hazard ratio (HR) 2.78; 95% CI 1.96-3.72;
p = 0.003) [9]. Finally, a controlled randomized study showed that statin
withdrawal at the time of admission for a hemispheric ischaemic stroke
was associated with a 19-fold increase in the risk of early neurological
deterioration compared with previous statin non-use (HR 19.01; 95% CI
1.96-184.09; p < 0.001) [10]. It was proposed that, once initiated, statin
treatment should not be interrupted except for a very good reason [11].
The inferior outcomes associated with statin withdrawal may be attrib-
uted to a “rebound” phenomenon [11]. Statins inhibit NAD(P)H oxidase
and superoxide production and upregulate the expression and activity of
endothelial nitric oxide synthase (eNOS) via inhibition of geranylgerany-
lation of RhoA and Rac1 GTPases [12]. RhoA negatively regulates eNOS
and Rac1 contributes to NAD(P)H-oxidase activation and superoxide pro-
duction [12]. Withdrawal of statin treatment leads to an overshoot acti-
vation of RhoA and Rac1 with considerable effects on nitric oxide bioavail-
ability, NAD(P)H-oxidase activity, and superoxide production [12]. The net
result is overt endothelial dysfunction and vasoregulatory dysfunction [11,
12].
Besides the studies showing an association between statin withdraw-
al with subarachnoid haemorrhage [8], mortality rates after an ischaemic
stroke episode [9] and neurological deterioration after an ischaemic stroke
episode [10], a contradictory report should also be mentioned [13]. This
report underlines the increased incidence of intracranial haemorrhage
associated with high statin dosage use in patients with a prior history of
stroke [13]. A more recent study, however, failed to verify the association
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between statin use in patients with a history of
ischaemic stroke with an increased risk of intracra-
nial haemorrhage [14]. Current evidence also indi-
cates  that  statins  should  be  discontinued  in
patients after a haemorrhagic stroke episode [15].
The 2011 Updated Society for Vascular Surgery
guidelines for the management of carotid artery
stenosis patients recommended statin use in all
patients scheduled for carotid revascularization aim-
ing at reducing low-density lipoprotein cholesterol
(LDL-C) levels < 100 mg/dl [16]. Due to these con-
troversial reports, in patients suffering an ischaemic
stroke, the possibly increased risk of future intracra-
nial haemorrhage should be counterbalanced with
the expected cardiovascular benefits associated
with statin use.
Ideally, the exact effects of statin withdrawal
should be investigated in a prospective random-
ized trial. Given the uniform results from the reports
performed so far, however [8-10], such a trial may
never be carried out due to considerable ethical lim-
itations. Physicians should ensure that patients not
on statins initiate a statin immediately after a vas-
cular event [11] or prior to vascular surgery [17].
More importantly, however, they should make sure
that patients on routine statin use do not discon-
tinue their treatment in order to avoid the occur-
rence of a first [8] (or recurrent) [9, 10] vascular
event.
Unfortunately, there is evidence that many car-
diovascular patients do not receive any lipid-low-
ering treatment [18]. Some physicians may be
reluctant to prescribe lipid-lowering drugs in all
patients, independent of their lipid levels. They
should bear in mind that serum LDL-C levels < 70
mg/dl do not seem to affect the adrenal axis func-
tion in terms of cortisol production, which is main-
ly synthesized from cholesterol [19]. Thus, physi-
cians may administer statins independently of the
patient’s lipid levels. 
These data suggest an increased physician alert-
ness for statin discontinuation in vascular patients.
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